Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Reaffirmed by Brookline Capital Management

Brookline Capital Management reiterated their hold rating on shares of Verrica Pharmaceuticals (NASDAQ:VRCA) in a research report report published on Wednesday, Marketbeat.com reports.

Other analysts also recently issued reports about the company. Needham & Company LLC decreased their price target on Verrica Pharmaceuticals from $16.00 to $12.00 and set a buy rating for the company in a research report on Thursday, August 15th. Royal Bank of Canada decreased their price target on Verrica Pharmaceuticals from $14.00 to $13.00 and set an outperform rating for the company in a research report on Thursday, August 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $11.75.

Verrica Pharmaceuticals Stock Down 9.7 %

Shares of NASDAQ:VRCA opened at $1.31 on Wednesday. The business’s 50 day simple moving average is $2.98 and its two-hundred day simple moving average is $5.91. The firm has a market cap of $55.57 million, a P/E ratio of -0.75 and a beta of 1.45. The company has a debt-to-equity ratio of 29.58, a quick ratio of 2.23 and a current ratio of 2.36. Verrica Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $4.70 million. As a group, research analysts forecast that Verrica Pharmaceuticals will post -1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Verrica Pharmaceuticals news, insider Joe Bonaccorso sold 25,461 shares of the firm’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $7.06, for a total value of $179,754.66. Following the completion of the sale, the insider now directly owns 106,931 shares of the company’s stock, valued at $754,932.86. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider Joe Bonaccorso sold 25,461 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $7.06, for a total transaction of $179,754.66. Following the sale, the insider now directly owns 106,931 shares in the company, valued at approximately $754,932.86. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ted White sold 32,469 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $7.06, for a total value of $229,231.14. Following the sale, the chief executive officer now owns 250,121 shares in the company, valued at approximately $1,765,854.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 42.60% of the company’s stock.

Institutional Trading of Verrica Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Simplify Asset Management Inc. bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at $2,041,000. Perceptive Advisors LLC grew its position in Verrica Pharmaceuticals by 40.9% during the fourth quarter. Perceptive Advisors LLC now owns 7,099,182 shares of the company’s stock worth $51,966,000 after buying an additional 2,060,199 shares in the last quarter. Avoro Capital Advisors LLC grew its position in Verrica Pharmaceuticals by 35.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock worth $29,280,000 after buying an additional 1,045,935 shares in the last quarter. Vanguard Group Inc. grew its position in Verrica Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock worth $7,511,000 after buying an additional 7,609 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in Verrica Pharmaceuticals during the second quarter worth about $50,000. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.